Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Core Viewpoint - Sage Therapeutics, Inc. has experienced an 11.1% decline in share price over the past month, underperforming the S&P 500, raising questions about its future performance leading up to the next earnings release [1]. Group 1: Earnings Report and Market Reaction - The most recent earnings report is crucial for understanding the key drivers affecting Sage Therapeutics [1]. - Fresh estimates for the company have trended upward over the past month, indicating a potential positive shift in investor sentiment [2]. Group 2: VGM Scores and Investment Strategy - Sage Therapeutics has a Growth Score of B, but it is lagging in Momentum Score with a D, and also received a D for Value, placing it in the bottom 40% for this investment strategy [3]. - The overall aggregate VGM Score for the stock is C, which is relevant for investors not focused on a single strategy [3]. Group 3: Future Outlook - Estimates for Sage Therapeutics have been broadly trending upward, although the magnitude of revisions suggests a downward shift [4]. - The company holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [4].